A preliminary study of 10 patients with severe COVID-19 \ ˈkō-vid-nīn-ˈtēn : a mild to severe respiratory illness that is caused by a coronavirus (Severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus), is transmitted chiefly by contact with infectious material (such as respiratory droplets), and is characterized especially by fever, cough, and shortness of breath and may progress to pneumonia and respiratory failure. symptoms showed that patients’ clinical symptoms rapidly improved within three days of receiving plasma from coronavirus co·ro·na·vi·rus : any of a family (Coronaviridae) of single-stranded RNA viruses that have a lipid envelope studded with club-shaped projections, infect birds and many mammals including humans, and include the causative agents of MERS, SARS, and COVID-19 survivors. Lung lesions also showed varying degrees of absorption one week after the treatment,.and the virus vi·rus | \ ˈvī-rəs : a disease-causing agent that is too tiny to be seen by the ordinary microscope, that may be a living organism or may be a very special kind of protein molecule, and that can only multiply when inside the cell of an organism disappeared in the blood of patients in seven days.
The convalescent plasma therapy study was based on results of 10 COVID-19 patients treated in China. Two COVID-19 patients in South Korea, a 71-year-old male and 67-year-old female, also were reported to have fully recovered with no side effects after receiving plasma transfusions. The reports raised the hope that the experimental plasma transfusion can help treat severe coronavirus cases.
Convalescent plasma therapy involves the use of plasma collected from individuals who have recovered from COVID-19.
Convalescent plasma therapy studies already are underway in the United States. Mount Sinai Health System in New York has injected 20 seriously ill coronavirus patients with convalescent plasma over the past few days.
The hope is that the antibodies in recovered patients’ blood will reverse the disease course or possibly prevent others, like healthcare workers, from getting the virus at all. The therapy, approved by the FDA under emergency protocols, is regulated as an investigational product. It allows health care providers and acute care facilities to obtain COVID-19 convalescent plasma from an FDA-registered facility to treat patients who are critically ill with the disease.
A consortium of more than 40 health institutions in the United States are working as part of the National COVID-19 Convalescent Plasma Project to conduct clinical trials and research effectiveness of the therapy in treating COVID-19.
Blood Banks, Hospitals Seeking Donors Among Recovered COVID-19 Patients
To be eligible to donate convalescent plasma, individuals must have evidence of COVID-19 documented by a laboratory test either by a diagnostic test (e.g., nasopharyngeal swab) at the time of illness or a positive serological test for SARS-CoV-2 ˈsärz-kō-ˈvē-ˈtü : the coronavirus (Severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus) that is the causative agent of COVID-19 antibodies after recovery. The donor also must have had a complete resolution of symptoms at least 28 days prior to donation or complete resolution of symptoms at least 14 days prior and negative COVID-19 test results.
The American Red Cross Blood Services is one of the licensed blood services providers seeking plasma donations from recovered COVID-19 patients.